Skip to main content
SpringerLink
Log in
Book cover

Regionale Therapie maligner Tumoren pp 127–138Cite as

Systemische Induktionschemotherapie bei Brustkrebs

  • Chapter

  • 1157 Accesses

Zusammenfassung

Brustkrebs ist ein zentrales öffentliches Gesundheitsproblem für Frauen weltweit. In den USA ist Brustkrebs weiterhin die häufigste Krebsart bei Frauen und die zweithäufigste krebsbedingte Todesursache. 2008 wurden in den USA 184.450 (26% aller Krebserkrankungen) neue Fälle von invasivem Brustkrebs diagnostiziert, und 40.390 Frauen starben an Brustkrebs [1].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.

    Article  PubMed  Google Scholar 

  2. Breast cancer facts and figures. www.cancer.org/ (2005–2006).

  3. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581.

    Article  PubMed  CAS  Google Scholar 

  4. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37 Suppl 8:4.

    Article  Google Scholar 

  5. Ries L, Eisner M, Kosary CL, et al. SEER cancer statistics review, 1975–2001. Bethesda: National Cancer Institute; 2004.

    Google Scholar 

  6. Berry DA, Cronin KA, Plevritis SK, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784.

    Article  PubMed  CAS  Google Scholar 

  7. Nissen-Meyer R, Kjellgren K, Malmio K, et al. Surgical adjuvant chemotherapy: results of one short course with cyclophosphamide after mastectomy for breast cancer. Cancer. 1978;41:2088–98.

    Article  PubMed  CAS  Google Scholar 

  8. Fisher B, Carbone P, Economou SG, et al. Phenylalanine mustard (L-PAM) in the management of the primary breast cancer: a report of early findings. N Engl J Med. 1975;292:117–22.

    Article  PubMed  CAS  Google Scholar 

  9. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–10.

    Article  PubMed  CAS  Google Scholar 

  10. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trail evaluating sequential methotrexate and fluorouracil in the treatment of patients with node negative breast cancer who have estrogen receptor negative tumors. N Engl J Med. 1989;320:473–8.

    Article  Google Scholar 

  11. Mansour EG, Grayr R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node negative breast cancer. N Engl J Med. 1989;320:485–90.

    Article  PubMed  CAS  Google Scholar 

  12. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28, 896 women. N Engl J Med. 1988;319: 1681–92.

    Google Scholar 

  13. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992;339:71–85.

    Google Scholar 

  14. Hortobagyi GN. Adjuvant systemic therapy for early breast cancer: progress and controversies. Clin Cancer Res. 2001;7:1839–42.

    PubMed  CAS  Google Scholar 

  15. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 1990;66:119–29.

    Article  PubMed  CAS  Google Scholar 

  16. Veronesi U, Saccozzi R, del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305:6–11.

    Article  PubMed  CAS  Google Scholar 

  17. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82:1539–45.

    Article  PubMed  CAS  Google Scholar 

  18. Bonadonna G, Valagussa P. The contribution of medicine to the primary treatment of breast cancer. Cancer Res. 1988;48:2314–24.

    PubMed  CAS  Google Scholar 

  19. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.

    PubMed  CAS  Google Scholar 

  20. Kurosumi M Significance of histopathological evaluation in primary therapy for breast cancer – recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer. 2004;11(2):139–47.

    Article  PubMed  Google Scholar 

  21. Bear H.D., Anderson S, Smith R.E, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicine plus cyclophosphamide for operable breast cancer: National Surgical Adjuvantand Bowel Project B27. J Clin.Oncol. 2006; 24: 2019–27.

    Article  PubMed  CAS  Google Scholar 

  22. Harris LN, Kaelin CM, Bellon JR, et al. Preoperative therapy for operable breast cancer. In: Harris JR, Lippman MC, Morrow M, editors. Diseases of the breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 929–43.

    Google Scholar 

  23. Hortobagyi GN, Singletary SE, Strom EA. Locally advanced breast cancer. In: Harris JR, Lippman MC, Morrow M, et al., editors. Diseases of the breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 951–69.

    Google Scholar 

  24. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24: 1940–9.

    Article  PubMed  Google Scholar 

  25. Buzdar AU. Preoperative chemotherapy treatment of breast cancer – a review. Cancer. 2007;110:2394–407.

    Article  PubMed  CAS  Google Scholar 

  26. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systematic therapy issues in operable disease. J Clin Oncol. 2008;26:814–9.

    Article  Google Scholar 

  27. Viale G, Bottiglieri L. Pathological definition of triple negative breast cancer. Eur J Cancer. 2009;45:5–10.

    Article  PubMed  Google Scholar 

  28. Cristofanilli M, Gonzales-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23:41–8.

    Google Scholar 

  29. Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacother. 2005;6:1477–91.

    Article  PubMed  CAS  Google Scholar 

  30. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancer. Proc Natl Acad Sci USA. 1999;96: 9212– 7.

    Article  PubMed  CAS  Google Scholar 

  31. Winer PE, Piccart-Gebhart MJ, Rugo HS, et al. Management of HER-2 positive breast cancer. In: ASCO Educational Book. Alexandria: ASCO; 2006. pp. 3–14.

    Google Scholar 

  32. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85.

    Article  PubMed  CAS  Google Scholar 

  33. Paik S., Shak S, Tang G, et al A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer N Engl J Med 2004; 351:2817–26.

    Article  CAS  Google Scholar 

  34. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726–3734.

    Article  PubMed  CAS  Google Scholar 

  35. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymphnode- negative, oestrogenreceptor- positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858–68.

    Article  PubMed  CAS  Google Scholar 

  36. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor- positive breast cancer. J Natl Cancer Inst 1997; 89: 1673–82.

    Article  PubMed  CAS  Google Scholar 

  37. Fan C, Oh DS, Wessels L, et al. Concordance among gene expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560–56.

    Article  PubMed  CAS  Google Scholar 

  38. Gianni L, Zambetti M, Clark K, et al, Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women with Locally Advanced Breast Cancer. J Clin Oncol. 2005; 23(29): 7265– 7277.

    Article  PubMed  CAS  Google Scholar 

  39. Peacock NW. Yardley DA, Hendricks CB, et al Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2- negative breast cancer with exploratory Oncotype DX assessments: A Sarah Cannon Research Institute phase II trial. 2011 ASCO Annual Meeting J Clin Oncol 29: 2011 (suppl; abstr 1066.

    Google Scholar 

  40. von Minckwitz G, Kummel S, du Bois A, et al. Individualized treatment strategies according to in vivo-chemosensitivity assessed by response after 2 cycles of neoadjuvant chemotherapy: final results of the Gepartrio study of the GBG. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio; 14–17 Dec 2006 (Abstr 42).

    Google Scholar 

  41. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results for the Aberdeen trial. Clin Breast Cancer. 2002;3(S2): S69–74.

    Article  PubMed  Google Scholar 

  42. Bear HD, Andeerson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019–27.

    Article  PubMed  CAS  Google Scholar 

  43. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.

    Article  PubMed  CAS  Google Scholar 

  44. Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicinbased regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004;22:2294–302.

    Article  PubMed  CAS  Google Scholar 

  45. Alvarez RH, Kau SW, Strom EA, et al. Phase II study of primary systemic therapy (PST) with doxorubicin (D) and docetaxel (T), then surgery (S), and radiation (RT), followed by use of non-cross-resistant adjuvant chemotherapy (Adj CT) with CMF based on pathologic response, in patients (pts) with locally advanced breast cancer (LABC): long-term results from study ID97-099, MD Anderson Cancer Center. J Clin Oncol. 2008;26:ASCO (Abstr 611).

    Google Scholar 

  46. Valero V. The role of systemic treatment for patients with residual disease after neoadjuvant chemotherapy. In: ASCO educational book. Alexandria: American Society of Clinical Oncology; 2009.

    Google Scholar 

  47. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guideline in oncology: breast cancer. V2 2009. www.nccn.org/ (2012).

  48. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathological complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicine chemotherapy: results of randomized trial in human epidermal growth factor receptor 2 positive operable breast cancer. J Clin Oncol. 2005;22:3676–85.

    Article  Google Scholar 

  49. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, The Lancet – 2010; 9712: , 377–84.

    Article  Google Scholar 

  50. Pierga J, Delaloge S, Espie M, et al A Multicenter randomized Phase II study of sequential epirubicine/cyclophosphamide followed docetaxel with or without celecoxib or trastuzumab according to HER2 status as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer ResTreat 2010; 122.2: 429–37.

    Article  CAS  Google Scholar 

  51. Coudert BP, Largillier R, Arnould L et al. Neoadjuvant therapy with trastuzumab,docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of a GETN(A) Group and OSMO Multicenter Phase II Trial (GETN[A]-1 trial) 547. J Clin Oncol 2007; 25:2678–84.

    Article  PubMed  CAS  Google Scholar 

  52. Guiu S, Liegard M, Favier L et al. Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Ann Oncol. 2011; 22:321–8.

    Article  Google Scholar 

  53. Untch M, Rezai M, Loib S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from de Gepar Quatro Study. J. Clin. Oncol. 2010; 28: 2024–31.

    Article  PubMed  CAS  Google Scholar 

  54. Bozovic-Spasojevic I, Azim Jr H.M, , Paesmans M, et al. Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe? Lancet Oncol 2011; 12(3):209–211.

    Article  PubMed  Google Scholar 

  55. Gianni L, Pienkowski T, Im YH, et al Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1): 25–32.

    Article  PubMed  CAS  Google Scholar 

  56. Untch M, Loibl S, Joachim Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline- taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. The Lancet Oncology, 2012. 13 (2), 135–144.

    Article  PubMed  CAS  Google Scholar 

  57. Baselga J, Bradbury I, Eidtmann H, et al Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo- ALTTO): a randomised, open-label, multicentre, phase 3 trial The Lancet 2012; 18 379: 633–400.

    Article  Google Scholar 

  58. Guarneri V, Frassoldati A, Bottini A, et al. Final results of a phase II randomized trial of neoadjuvant anthracyclinetaxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). J Clin Oncol 2011; 29: (suppl; abstr 507).

    Google Scholar 

  59. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.

    Article  PubMed  CAS  Google Scholar 

  60. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB- 1- and/ or ErbB2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–16.

    PubMed  CAS  Google Scholar 

  61. Forero-Torres A, Saleh MN, Galleshaw JA, et al. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor- positive breast cancer. Clin Breast Cancer. 2010; 10(4): 275–80.

    Article  PubMed  CAS  Google Scholar 

  62. Baar J, Silverman P, Lyons J, et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res. 2009; 15(10): 3583–90.

    Article  PubMed  CAS  Google Scholar 

  63. Ferrari B, Scarano E, Pietri et al, Bevacizumab combined with chemo endocrine preoperative therapy in locally advanced operable breast cancers SABCS.2007 (Astract 4063).

    Google Scholar 

  64. Balduzzi A, Montagna E, Bagnardi V, et al. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.Anticancer Drugs. 2009;20(3):197–203.

    Article  PubMed  CAS  Google Scholar 

  65. Ryan PD, Tung NM, Isakoff, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC). J Clin Oncol 2009; 27 (suppl: abstract 551).

    Google Scholar 

  66. Greil R, Moik M, Reitsamer R, Ressler S, et al. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. Eur J Surg Oncol. 2009;35(10):1048–54.

    Article  PubMed  CAS  Google Scholar 

  67. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. N Engl J Med 2012;366: 299–309.

    Article  Google Scholar 

  68. Bear HD, Tang G, Rastogi P, et al. Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer N Engl J Med 2012;366:310–20.

    Article  PubMed  CAS  Google Scholar 

  69. Mamounas E, Kumar R. Surgical considerations for patients treated with neoadjuvant chemotherapy. In: 2007 Educational book. Alexandria: American Society of Clinical Oncology; 2007. pp. 56–58.

    Google Scholar 

  70. Chen T, Meric-Bernstam F, Hunt KK, et al. Breast-conserving therapy after neoadjuvant chemotherapy: The M.D. Anderson Cancer Center experience. J Clin Oncol. 2004;22:2303–2312.

    Article  PubMed  Google Scholar 

  71. Buchholz. The use of radiation for patients with breast cancer treated with neoadjuvant therapy. In: 2007 Educational book. Alexandria: American Society of Clinical Oncology; 2007. pp. 60–62.

    Google Scholar 

  72. Huang EH., Tucker SL, Strom EA, et al. Radiation treatment improves local-regional control and cause-specific survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22:4691–4699.

    Article  PubMed  Google Scholar 

  73. McGuire SE, Gonzalez-Angulo AM, Tucker SL, et al. Postmastectomy radiation improves the outcome of patients with stage III breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007; 68(4):1004–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Oncologie Médicale, Groupe Hospitalier Pitié Salpêtrière, 47 Boulevard de I’Hôpital, 75013, Paris, Frankreich

    François-Michel Delgado MD, PhD, Maria Angeles Gil-Delgado MD & Prof. David Khayat

Authors
  1. François-Michel Delgado MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Angeles Gil-Delgado MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. David Khayat
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medias Klinikum Burghausen, Burghausen

    Karl Reinhard Aigner

  2. University of Sydney, Sydney, Australia

    Frederick O. Stephens

  3. Universitätsklinikum Frankfurt, Frankfurt

    Thomas J. Vogl

  4. Universitätsklinikum Gießen, Gießen

    Winfried Padberg

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Delgado, FM., Gil-Delgado, M.A., Khayat, D. (2013). Systemische Induktionschemotherapie bei Brustkrebs. In: Aigner, K.R., Stephens, F.O., Vogl, T.J., Padberg, W. (eds) Regionale Therapie maligner Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35014-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-35014-6_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-35013-9

  • Online ISBN: 978-3-642-35014-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation